BridgeBio Pharma Free Cash Flow 2018-2026 | BBIO
BridgeBio Pharma annual/quarterly free cash flow history and growth rate from 2018 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- BridgeBio Pharma free cash flow for the quarter ending March 31, 2026 was 0.00, a year-over-year.
- BridgeBio Pharma free cash flow for the twelve months ending March 31, 2026 was , a year-over-year.
- BridgeBio Pharma annual free cash flow for 2025 was $0B, a 100% decline from 2024.
- BridgeBio Pharma annual free cash flow for 2024 was $-0.522B, a 1.39% decline from 2023.
- BridgeBio Pharma annual free cash flow for 2023 was $-0.529B, a 24.68% increase from 2022.
| BridgeBio Pharma Annual Free Cash Flow | |
|---|---|
| 2025 | |
| 2024 | -521.66 |
| 2023 | -529.03 |
| 2022 | -424.32 |
| 2021 | -511.18 |
| 2020 | -407.23 |
| 2019 | -256.23 |
| 2018 | -138.82 |
| 2017 | -40.95 |
| BridgeBio Pharma Quarterly Free Cash Flow | |
|---|---|
| 2026-03-31 | |
| 2025-12-31 | |
| 2025-09-30 | -390.55 |
| 2025-06-30 | -280.51 |
| 2025-03-31 | -199.24 |
| 2024-12-31 | -521.66 |
| 2024-09-30 | -326.29 |
| 2024-06-30 | -145.58 |
| 2024-03-31 | -220.23 |
| 2023-12-31 | -529.03 |
| 2023-09-30 | -403.77 |
| 2023-06-30 | -258.12 |
| 2023-03-31 | -144.33 |
| 2022-12-31 | -424.32 |
| 2022-09-30 | -330.27 |
| 2022-06-30 | -194.35 |
| 2022-03-31 | -161.49 |
| 2021-12-31 | -511.18 |
| 2021-09-30 | -374.75 |
| 2021-06-30 | -246.73 |
| 2021-03-31 | -152.73 |
| 2020-12-31 | -407.23 |
| 2020-09-30 | -308.68 |
| 2020-06-30 | -176.45 |
| 2020-03-31 | -88.40 |
| 2019-12-31 | -256.23 |
| 2019-09-30 | -178.28 |
| 2019-06-30 | -127.90 |
| 2019-03-31 | -59.57 |
| 2018-12-31 | |
| 2018-09-30 | -91.67 |
| 2017-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |